<Varney said multiple parties, but the extent of their interest is another question. I still think designing a pivotal trial for RD could be seen by potential partners as daunting. To quote Neuro - "looking for a target event that is relatively uncommon, and would become even less common in the more rigorously monitored climate of a clinical trial, waiting for enough cases to come through to generate enough of a database to establish superiority to naloxone will not be a rapid or inexpensive process.">
I agree but...a company that successfully coupled CX717 (or back-up) with their opiate would have the market to themselves. If I were in that business I might consider a deal just to keep my rivals from partnering with Cortex, even if I haven't yet figured out how to run a trial. Perhaps a little paranoia between prospective partners is what we should hope for.
As has also been talked about, a safer way to administer opiates would make Cortex and their partner a boatload of money.
News 
Market Data 
Discover 
AI
